Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 9/20 | 0.40 |
| ▸ | CA2 | P00918 | 9/20 | 0.40 |
| ▸ | CA12 | O43570 | 5/20 | 0.40 |
| ▸ | CA9 | Q16790 | 5/20 | 0.40 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CYP3A43 | Q9HB55 | 1/20 | 0.37 |
| ▸ | METAP2 | P50579 | 4/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | XBP1 | P17861 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1649052 | 0.94 | CA1 (0.41) | CA1CA2CA12CA9CYP1A1 | |
| SCHEMBL1648412 | 0.92 | CA1 (0.40) | CA1CA2CA12CA9CYP1A1 | |
| SCHEMBL1648204 | 0.91 | CA12 (0.37) | CA1CA2CA12CA9CYP1A1 | |
| SCHEMBL1648088 | 0.91 | METAP2 (0.45) | CA1CA2CA12CA9CYP1A1 | |
| SCHEMBL1648173 | 0.89 | ALDH1A1 (0.39) | CA1CA2CA12CA9CYP1A1 | |
| SCHEMBL1648314 | 0.89 | NPSR1 (0.37) | CA1CA2CA12CA9METAP2 | |
| SCHEMBL1649223 | 0.88 | BRD4 (0.39) | CA1CA2CA12CA9CYP1A1 | |
| SCHEMBL1648296 | 0.86 | PDK2 (0.37) | METAP2PDK2 | |
| SCHEMBL1649273 | 0.86 | MALT1 (0.39) | CA1CA2CA12CA9METAP2 | |
| SCHEMBL1648453 | 0.86 | NPSR1 (0.36) | METAP2ALDH1A1TP53MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2486004-B1 | SULPHONE COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY | ZAFGEN INC (US) | 2017-05-03 | — | — | EP | disclosed |
| EP-2486004-B1 | SULPHONE COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY | ZAFGEN INC (US) | 2017-05-03 | — | — | EP | disclosed |
| US-20160051531-A1 | SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2016-02-25 | — | — | US | disclosed |
| US-9067905-B2 | Sulphone compounds and methods of making and using same | ZAFGEN, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067905-B2 | Sulphone compounds and methods of making and using same | ZAFGEN, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067905-B2 | Sulphone compounds and methods of making and using same | ZAFGEN, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-20130053364-A1 | Sulphone Compounds and Methods of Making and Using Same | ZAFGEN, INC. | 2013-02-28 | — | — | US | disclosed |
| US-20130053364-A1 | Sulphone Compounds and Methods of Making and Using Same | ZAFGEN, INC. | 2013-02-28 | — | — | US | disclosed |
| US-20130053364-A1 | Sulphone Compounds and Methods of Making and Using Same | ZAFGEN, INC. | 2013-02-28 | — | — | US | disclosed |
| EP-2486004-A2 | SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME | Zafgen Corporation (US) | 2012-08-15 | — | — | EP | disclosed |
| WO-2011044506-A2 | SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN CORPORATION (US) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011044506-A2 | SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN CORPORATION (US) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160051531-A1 | SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, DNPEP, STS | CA1 1032/4885CA2 639/4885CA12 711/4885 |
| US-20130053364-A1 | Sulphone Compounds and Methods of Making and Using Same | METAP2, DNPEP, STS | CA1 1032/4885CA2 639/4885CA12 711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.